Bispecific antibodies (BsAbs) offer transformative therapeutic potential, but their complex, non-native structure creates production challenges such as mispairing, low yield, and purification difficulty. Backed by an automated, high-throughput workflow and extensive project experience, Biointron’s BsAb production platform provides a fast-track service delivering high-quality products within 2–3 weeks. This overview highlights key service features, platform advantages, and representative approaches that address challenging bispecific antibody production projects for advanced therapeutic development worldwide.